ADMA与糖尿病血管并发症的研究进展  

Research Progress of Asymmetric Dimethylarginine in Diabetic Vascular Complications

作　　者：杜美容[1] 李元建[1] 江俊麟[1] 

机构地区：[1]中南大学药学院药理系,湖南省长沙市410008

出　　处：《中国动脉硬化杂志》2015年第8期845-850,共6页Chinese Journal of Arteriosclerosis

基　　金：国家自然科学基金面上项目(81373408)

摘　　要：非对称性二甲基精氨酸(ADMA)的蓄积不仅加速糖尿病的发生发展,还与糖尿病心脑血管疾病、糖尿病肾病和糖尿病视网膜病变等血管并发症密切相关。ADMA可通过抑制一氧化氮合酶(NOS)活性,减少NO合成,促使血管内皮功能受损,介导糖尿病血管疾病的发生发展。The accumulation of asymmetric dimethylarginine（ ADMA） has been demonstrated to be correlated with the development and progression of diabetic vascular complications including cardiovascular or cerebrovascular disease,nephropathy and retinopathy. ADMA can inhibit nitric oxide synthase（ NOS） activity and reduce nitric oxide（ NO） synthesis,thereafter to promote endothelial dysfunction and mediate the occurrence and development of diabetic vascular diseases.

关 键 词：非对称二甲基精氨酸 糖尿病大血管病变 糖尿病微血管病变 

分 类 号：R5[医药卫生—内科学]